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Recent ﬁndings have implicated Fas/Fas ligand (FasL) in mediating the death of keratinocytes in spongiotic le-
sions. We asked whether dying keratinocytes could potentially initiate a protective response of the skin to limit the
destruction of the epidermis in the spongiotic areas. In addition to apoptosis, treatment of keratinocyte cultures in
vitro with FasL triggers a profound phoshorylation of the epidermal growth factor receptor (EGFR) and of its
downstream effectors ERK and protein kinase B (PKB/Akt). Using a variety of inhibitors and blocking antibodies,
we demonstrated that: (i) apoptosis is required for the generation of the signal(s) leading to the activation of EGFR,
ERK, and Akt; (ii) the activation of EGFR, ERK, and Akt by FasL is indeed mediated by its bona fide receptor Fas;
(iii) the activation of EGFR is essential for the subsequent activation of ERK and Akt; and (iv) apoptotic keratin-
ocytes secrete soluble EGFR ligands (including amphiregulin) that are processed from membrane-bound proligand
forms by metalloproteinase(s). Our ﬁndings demonstrate a potential mechanism for the restriction and repair of
spongiotic damage in eczemas.
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Atopic dermatitis (AD) and allergic contact dermatitis (ACD)
are common inflammatory skin diseases that belong to the
heterogeneous group of eczematous dermatitides or ecze-
mas. A common histopathological feature of eczemas is the
formation of exudative epidermal vesicles that are disrup-
tive to the normal barrier function of the skin. Although
vesicle formation in eczemas has been largely attributed to
rupturing of keratinocyte attachments as a result of inter-
cellular edema (spongiosis) (Schwarz, 2000 and references
therein), recent findings suggest that keratinocyte death
plays a major role in vesicle formation (Schwarz, 2000;
Trautmann et al, 2000). This keratinocyte death appears to
be apoptotic and to be mediated by Fas ligand (FasL), de-
livered to the epidermis by infiltrating T lymphocytes and
acting on its receptor, Fas, expressed on the surface of
keratinocytes (Trautmann et al, 2000).
The question of how vesicle formation is restricted to
avoid progressive destruction of the skin is of clinical im-
portance. The defense of the epidermis against destruction
could be mediated by the eventual resolution of the under-
lying inflammatory process and the subsequent reduction in
the levels of FasL in the epidermis. The epidermal keratin-
ocytes may also respond to the wave of apoptosis by trig-
gering pro-survival programs. Such pro-survival programs
could act by rendering keratinocytes resistant to FasL-de-
pendent apoptosis by, for instance, downregulating the
expression of Fas or upregulating the expression of anti-
apoptotic proteins. Alternatively, the pro-survival programs
may not be directed at rescuing the keratinocytes that are
targeted by FasL, but instead at increasing the proliferation of
basal keratinocytes to replenish the cells lost to apoptosis.
Here, we have investigated the occurrence of both
apoptosis and hyperproliferation in experimentally induced
allergic contact dermatitis. Indeed, eczematous epidermis
displayed the co-existence of both ectopic cell death by
apoptosis and increased proliferation of keratinocytes, sug-
gesting that the two events may be mechanistically linked.
To investigate whether apoptotic keratinocytes are capable
of generating and communicating mitogenic signals, we
employed in vitro studies in a human keratinocyte mono-
culture system. We found that treatment of keratinocytes
with FasL triggers, in addition to apoptosis, a profound
phoshorylation of the epidermal growth factor receptor
(EGFR) and of its downstream effectors, the extracellular
signal-activated kinases (ERK) and protein kinase B (PKB/
Akt). Using specific small molecule inhibitors and blocking
antibodies, we found that the apoptotic caspase cascade
triggered by FasL results in the increased production,
processing, and shedding of soluble ligands of EGFR, one
Abbreviations: ACD, allergic contact dermatitis; AD, atopic der-
matitis; AR, amphiregulin; EGF(R), epidermal growth factor (recep-
tor); ERK, extracellular signal-activated kinase(s); FasL, Fas ligand;
HB-EGF, heparin-binding EGF; HEKn, human epidermal keratin-
ocytes, neonatal; PARP, poly(ADP)ribose polymerase; PKB/
Akt, protein kinase B; SADBE, squaric acid dibutylester; TUNEL,
terminal deoxynucleotidyl transferase-mediated dUTP nick end
labeling
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of which was identified as amphiregulin. Thus, we demon-
strate that keratinocytes are capable of responding to pro-
apoptotic stimuli by mounting an anti-apoptotic survival
program. Finally, we present evidence that the pro-survival/
mitogenic program(s) initiated by apoptotic keratinocytes
do not rescue the keratinocytes that are directly targeted
by apoptotic stimuli, but instead increase the proliferation
of basal keratinocytes to replenish the loss of cells by
apoptosis.
Results and Discussion
Co-existence of cell death and increased proliferation
in eczematous epidermis Seven days post-application of
squaric acid dibutylester (SADBE) to the skin of sensitized
volunteers, biopsies from the affected area displayed abun-
dance of epidermal vesicles and marked thickening of the
epidermis, consistent with inter- and intracellular edema
(Fig 1, panels c and d; Fig 2, panels c and f) and increased
proliferation (see below). The appearance in the ACD lesion
of epidermal cells with abnormal nuclei (either ‘‘hollow’’ in
appearance, Fig 1, panel c, ﬁlled arrowheads, or pyknotic,
Fig 3, panel d, asterisk) suggested ongoing cell death. Al-
though programmed cell death is the end point of normal
keratinocyte differentiation, such type of cell death lacks the
classical features of apoptosis, e.g., caspase activation and
chromatin fragmentation (Lippens et al, 2000; Takahashi
et al, 2000). In contrast, the epidermal material collected
either 2 or 7 d post-SADBE administration displayed termi-
nal deoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL)-positive cells, suggesting the possibility of
ongoing apoptosis (Fig 1, panels b–d and Fig 2, panels b, c,
e, and f) although the occurrence of other modes of cell
death in our experimental model of dermatitis cannot be
excluded.
To investigate the relationship between cell death and the
state of differentiation of keratinocytes in ACD, we co-
stained biopsied material for both TUNEL and keratin 5, a
marker for stratum basale keratinocytes. Interestingly, the
area of epidermal thickening in 2 and, especially, in 7 d ACD
stained positive for keratin 5 and the majority of the TUNEL-
positive cells were interspersed within this expanded area
of keratin 5 expression (Fig 2, panels b, c, e, and f). Staining
for keratin 1, a marker for keratinocytes in stratum spinosum
did not display a significant expansion of this layer in ACD
(not shown). Thus, the bulk of epidermal thickening in ACD
was due, in addition to spongiosis, to an increase in the
number of cells displaying the characteristics of undiffer-
entiated basal keratinocytes. Furthermore, the epidermal
thickening in ACD was co-existent with ongoing keratin-
ocyte death (Figs 1 and 2).
In order to determine the proliferation potential of ACD
epidermis, we immunostained for Ki-67, a marker for cy-
cling cells (Gerdes et al, 1991). A  2-fold (2.07  0.39,
po0.05) increase in the appearance of Ki-67-positive cells
was detected in the ACD skin in comparison to the healthy
skin of the same volunteer (exemplified in Fig 3). Both cell
death (Fig 3, panels b and d, see pyknotic nuclei labeled
with an asterisk) and increased renewal of the epidermal
cells (Ki-67 staining) were concurrent within the eczematous
lesion. To confirm that the increased epidermal thickness
and Ki-67-positivity in ACD is indeed associated with in-
creased keratinocyte number, we also counted nucleated
cells per millimeter of basal lamina in healthy (control) and
48 h ACD biopsies from the volunteer presented in Figs 1
and 2. Although the control epidermis contained 382  29
nucleated cell per millimeter of basal lamina, the ACD ep-
idermis displayed 529  18 nucleated cell per millimeter of
basal lamina, indicative of  39% (po0.05) increase in cell
number in ACD epidermis. Due to the massive epidermal
disruption in 7 d ACD (Figs 1 and 2), an exact count of
nucleated cells per millimeter of basal lamina could not be
obtained.
The origin and nature of the mitogenic signals in the
eczematous epidermis: a hypothesis What is the source
of mitogenic signals that govern the increased proliferation
of keratinocytes detected in ACD? Although the diffusion of
keratinocyte-stimulating mitogens from the dermis is well
established (Szabowski et al, 2000; Angel et al, 2001; Maas-
Szabowski et al, 2001; Angel and Szabowski, 2002), we and
others have reported that keratinocytes sustain active pro-
liferative and pro-survival signaling cascades by means of
autocrine production of secreted ligands for the epidermal
growth factor receptor (Cook et al, 1991; Pittelkow et al,
1993; Piepkorn et al, 1998; Jost et al, 1999; Iordanov et al,
2002). Therefore, it is possible that at least some of the
mitogenic signals driving the increased proliferation in ACD
epidermis are keratinocyte-derived. We further speculated
that the dying keratinocytes themselves might generate
some of these mitogenic signals. To test this hypothesis, we
took advantage of the recent progress made in under-
standing keratinocyte cell death in eczemas. Trautmann
et al (2000) have discovered that epidermal apoptosis in
eczemas (both AD and ACD) is mediated by activation of
the death receptor Fas on the surface of keratinocytes.
Therefore, we employed FasL-mediated apoptosis in kera-
tinocyte monoculture to investigate the ability of apoptotic
epidermal cells to produce mitogenic signals.
Hexameric soluble Fc:FasL triggers apoptosis and
phosphorylation of EGFR, ERK, and Akt in human ker-
atinocytes To determine the susceptibility of human kera-
tinocytes to FasL-triggered apoptosis, we treated either
immortalized human keratinocytes (HEKn (human epidermal
kerationcytes, neonatal)-E6/E7) or primary human keratin-
ocyte explants (HEKn, passages 3–6) with Fc:FasL, a re-
combinant hexameric form of human FasL (Holler et al,
2003). Both HEKn and HEKn-E6/E7 displayed time-de-
pendent apoptosis in response to Fc:FasL as measured by
the cleavage of caspase substrate poly(ADP)ribose polym-
erase (PARP; Fig 4A, lanes 4–6; Fig 4B, lanes 4–6 and
10–12). Surprisingly, the treatment with Fc:FasL resulted in
a pronounced phosphorylation of EGFR, as determined by
immunoblot analyses using two phosphoepitope-specific
antibodies (Fig 4A, lanes 4–6; Fig 4B, lanes 4–6 and 10–12;
directed against phosphotyrosine residues 1173 and 1068).
Whereas the effect of Fc:FasL on the phosphorylation of
EGFR in HEKn–E6/E7 was straightforward to interpret, the
effect of Fc:FasL on the phosphorylation of EGFR in HEKn
was superimposed on the more pronounced decrease in
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the total EGFR levels that is coincidental with apoptosis
(Fig 4B, compare PARP and EGFR panels, lanes 11 and 12)
in these cells. Taking into consideration the levels of both
total EGFR and phosphorylated EGFR (Fig 4B, compare
lanes 8 and 9 to lanes 11 and 12), it is apparent that there is
an net increase in the phosphorylation of EGFR in the
Fc:FasL-treated HEKn at 2 and 4 h after the addition of
Fc:FasL.
We have previously demonstrated that the basal activ-
ities of the ERK and Akt protein kinases in primary HEKn
and in HEKn-E6/E7 are exclusively regulated by autocrine
stimulation of the EGFR (Iordanov et al, 2002). Consistent
with the activation of EGFR by Fc:FasL, we observed that
both ERK and Akt became phosphorylated following ad-
ministration of Fc:FasL (Fig 4A, lanes 4–6). The phosphor-
ylation of EGFR, ERK, and Akt in response to EGF was, as
expected, not accompanied by apoptosis (Fig 4A, compare
lanes lanes 4–6 to lanes 7–8). To investigate whether the
phosphorylation of EGFR in response to Fc:FasL was me-
diated by Fas, the bona ﬁde receptor for FasL, we employed
ZB4, a Fas-neutralizing antibody. Indeed, ZB4 abrogated
not only the apoptotic response of HEKn–E6/E7 to Fc:FasL,
but also the phosphorylation of EGFR (Fig 5A, compare
lanes 3 to lanes 4).
Secretion of soluble EGFR ligand(s) by Fc:FasL-treated
keratinocytes We next tested whether Fc:FasL-treated
keratinocytes produce soluble ligands capable of activat-
ing EGFR. To this end, we prepared conditioned media from
either untreated or Fc:FasL-treated HEKn–E6/E7 (referred
Figure 2
Spongiosis, apoptosis, and keratin 5
expression in allergic contact dermati-
tis (ACD). Representative biopsies from
the same subject as in Fig 1. The sections
were stained first for terminal deoxynuc-
leotidyl transferase-mediated dUTP nick
end labeling (crimson) and followed by
immunostaining for keratin 5 (yellow–
brown). The rectangles in panels a–c
indicate the respective locations in the
epidermis of the areas represented in
panels d–f.
Figure 1
Spongiosis and apoptotic cell death in
allergic contact dermatitis (ACD). Rep-
resentative biopsies from squaric caid di-
butylester (SADBE)-induced ACD and
adjacent normal skin taken either 2 or 7
d after the challenge with SADBE. The
subject developed massive vesiculation.
The sections were stained first for termi-
nal deoxynucleotidyl transferase-mediat-
ed dUTP nick end labeling (TUNEL)
(crimson; examples indicated with filled
arrowheads) and then counterstained with
hematoxylin (blue; examples indicated
with empty arrowheads). Note that the
TUNEL-positive nuclei exclude hematoxylin, thus allowing a clear distinction between apoptotic and non-apoptotic cells. Paired asterisks indicate
examples of neighboring apoptotic (crimson) and healthy (blue) nuclei. The rectangle in panel d indicates the location within the thickened epidermis
of the area represented in panel c. Dashed lines indicate the location of the basement membrane.
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to as ‘‘donor’’ cells; see Experimental design in the legend to
Fig 5B) and tested the ability of these conditioned media to
trigger phosphorylation of EGFR in naı¨ve (‘‘acceptor’’) cells.
Indeed, the conditioned medium from the Fc:FasL-treated
donor cells, but not the conditioned medium from the un-
treated donor cells, contained activity that triggered an
early (within 0.5 h) phosphorylation of EGFR and ERK
(Fig 5B, compare lanes 1 and 5). For two reasons, this ac-
tivity was clearly different from the Fc:FasL itself present in
the conditioned medium. First, the phosphorylation of EGFR
and ERK in the acceptor cells occurred before the onset of
apoptosis, triggered by the residual Fc:FasL in the condi-
tioned medium (Fig 5B, lane 5, compare PARP to the
phosphorylation of EGFR and ERK). Second, the phosphor-
ylation of EGFR and ERK in response to the Fc:FasL-con-
ditioned medium proceeded unaffected when the accep-
tor cells were pretreated with ZB4 to neutralize Fas (Fig 5B,
compare lanes 5 and 7).
Caspase activity is required for the production of EGFR
ligands by Fc:FasL-treated keratinocytes To determine
whether the production of soluble EGFR ligands in response
to Fas ligation could be mediated by caspase activity, we
employed zVADfmk, a non-specific pan-caspase inhibitor,
and zIETDfmk, a more specific caspase 8 inhibitor (Thorn-
berry et al, 1997; Garcia-Calvo et al, 1998). As shown in
Fig 6, both inhibitors abrogated completely the apoptosis
triggered by Fc:FasL (measured by determining the cleav-
age of either caspase 8 or PARP; Fig 6, compare lanes
10–12 to lanes 13–18). Under these conditions, both inhib-
itors strongly diminished the Fc:FasL-induced phosphor-
ylation of EGFR, ERK, and Akt (Fig 6, compare lanes 10–12
to lanes 13–18). We concluded, therefore, that caspase
activity is required for the activation of production and/or
shedding of EGFR ligands by apoptotic keratinocytes.
Metalloprotease activity is required for the secretion of
EGFR ligands by Fc:FasL-treated keratinocytes Mem-
bers of the EGF family of growth factors, including trans-
forming growth factor-a (TGF-a), amphiregulin (AR), and
heparin-binding EGF (HB-EGF), are expressed as trans-
membrane precursors that are cleaved at one or more sites
in the extracellular domain to release soluble growth factor
(Lee et al, 2003). The available experimental evidence im-
plicates the tumor necrosis factor-a converting enzyme
(TACE/ADAM17) as one relevant protease responsible for
the maturation of TGF-a, AR, and HB-EGF in vivo (Sunn-
Figure 3
Increased proliferation in allergic contact dermatitis (ACD). Rep-
resentative biopsies from a subject (different from the one presented in
Figs 1 and 2) taken 7 d post-SADBE and stained immunohistochem-
ically for Ki-67. Note the concurrent existence within the eczematous
lesion of both cell death (pyknotic nuclei labeled with an asterisk) and
increased Ki-67 staining. The rectangles in panels a and b indicate the
respective locations in the epidermis of the areas represented in panels
c and d.
Figure4
Induction of apoptosis and phosphorylation of epidermal growth
factor receptor (EGFR), extracellular signal-activated kinase (ERK),
and protein kinase B (Akt)1 in response to Fc:FasL (Fas ligand)
treatment of keratinocytes. (A) HEKn (human epidermal keration-
cytes, neonatal)-E6/E7 were plated and grown in basal keratinocyte
medium (BKM)þ exoGF. The cells were extensively washed with
BKMexoGF and incubated in BKMexoGF for 2 h before treatments.
Therefore, at the time of treatments, the basal levels of phosphorylation
of EGFR and its downstream effectors are determined by the secretion
of autocrine factors by the cells, as we have shown previously (Iorda-
nov et al, 2002). The cells were then treated, for the indicated times,
with either Fc-FasL (see Materials and Methods for concentrations
used) or EGF (50 ng per mL). The cells were harvested as described in
Materials and Methods and cell lysates were processed for immunoblot
analyses. Apoptosis was assessed by determining the cleavage of po-
ly(ADP)ribose polymerase. The phosphorylation state of EGFR, ERK,
and Akt1 was assessed using phosphoepitope-specific antibodies. (B)
HEKn-E6/E7 and HEKn were deprived of exogenous growth factors
and treated with Fc-FasL for the indicated times with as in (A) and
processed for immunoblot analyses with the indicated antibodies.
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arborg et al, 2002; Borrell-Pages et al, 2003; Gschwind et al,
2003; Jackson et al, 2003; Lee et al, 2003) although the
identity of the protease(s) responsible for the maturation of
these EGFR ligands in keratinocytes is not known. Ilomastat
(galardin, GM6001), a broad specificity metalloproteinase
inhibitor (Schultz et al, 1992) inhibits TACE (Solorzano et al,
1997) and blocks bombesin- and lysophosphatidic acid-in-
duced EGF receptor transactivation (Santiskulvong and
Rozengurt, 2003). We pretreated HEKn-E6/E7 with ilomas-
tat before stimulation of the cells with Fc:FasL. Both EGFR
Figure 5
The phosphorylation of epidermal growth factor receptor (EGFR) in
response to Fc:FasL (Fas ligand) depends on Fas ligation and on
secreted soluble EGFR ligands. (A) HEKn (human epidermal
kerationcytes, neonatal)-E6/E7 were treated with Fc:FasL for 2 h as
in Fig 4, except that, where indicated, zVADfmk (50 mM) or ZB4 (2 mg
per mL) were given to the cells for 30 min before the treatment. Each
experimental point was performed in duplicate. Immunoblot analyses
using phosphoepitope-specific antibodies to EGFR as indicated.
Apoptosis was assessed by determining the cleavage of caspase 8
or poly(ADP)ribose polymerase (PARP). The light and heavy chains of
the ZB4 antibody appear in the gel because of internalization and/or
adherence of the antibody to the cell surface. (B) Experimental Design:
HEKn-E6/E7 were left untreated (‘‘control cells’’) or were treated with
Fc:FasL. Both control and treated cells were extensively washed with
BKMexoGF and incubated in BKMexoGF for 2 h before treatment
with Fc:FasL. Two hours after the treatment, the media from the control
and treated cells were collected and cleared from cell debris by cen-
trifugation. These media were designated ‘‘conditioned medium from
control cells’’ and ‘‘conditioned medium from Fc:FasL-treated cells’’,
respectively. The ‘‘donor’’ cells, which have produced the conditioned
media, were discarded. Naı¨ve (‘‘acceptor’’) HEKn-E6/E7 were exten-
sively washed with BKMexoGF and incubated in BKMexoGF for 1.5
h. Then, where indicated, the ZB4 Fas-blocking antibody was given to
the cells for 0.5 h. Finally, the medium of the ‘‘acceptor’’ cells was
exchanged, as indicated, with either one or the other conditioned me-
dia for the indicated times (0.5 or 2 h). During the time of incubation
with conditioned media, the ZB4 antibody was continuously present
where indicated, in order to prevent the residual Fc:FasL from the
conditioned medium from acting on the ‘‘acceptor’’ cells. That ZB4
indeed effectively prevented residual carry-over Fc:FasL from acting on
the ‘‘acceptor’’ cells is evident from the lack of PARP cleavage in lane 8
(compared to lane 6). The phosphorylation states of EGFR and ERK
were assessed in immunoblot analyses using phosphoepitope-specific
antibodies.
Figure6
Caspase activity is required for the activation of epidermal growth
factor receptor (EGFR), extracellular signal-activated kinase (ERK),
and protein kinase B (Akt)1 by Fc:FasL (Fas ligand). HEKn (human
epidermal kerationcytes, neonatal)-E6/E7 were treated with Fc:FasL.
Where indicated, zVADfmk or zIETDfmk (all at 50 mM) or solvent vehicle
(DMSO) were given to the cells for 30 min before the treatment. At the
indicated times, the phosphorylation states of EGFR, ERK, and Akt1
were assessed in immunoblot analyses using phosphoepitope-specific
antibodies. Apoptosis was assessed by determining the cleavage of
poly(ADP)ribose polymerase.
Figure7
The Fc:FasL (Fas ligand)-induced soluble epidermal growth factor
receptor (EGFR) ligands are secreted following proteolytic cleav-
ages of their membrane-bound proforms. The cells were treated
with Fc:FasL. Where indicated, ilomastat (25 mM) or solvent vehicle
(DMSO) were given to the cells for 30 min before the treatment. At the
indicated times, the phosphorylation states of EGFR and ERK were
assessed in immunoblot analyses using phosphoepitope-specific an-
tibodies. Apoptosis was assessed by determining the cleavage of po-
ly(ADP)ribose polymerase.
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and ERK phosphorylations were reduced in the presence of
ilomastat (Fig 7, compare lanes 9–12 to lanes 13–16).
Ilomastat had no apparent effect on Fc:FasL-induced
apoptosis, measured by PARP cleavage, indicating that
the drug did not interfere with the binding of Fc:FasL to Fas
or with caspase activity (Fig 7, compare lanes 9–12 to lanes
13–16). Furthermore, ilomastat had no effect on the ability
of exogenous EGF to trigger phosphorylation of EGFR and
ERK (not shown). We concluded that proteolytic maturation
of membrane-bound precursors of one or more EGFR lig-
ands is responsible for at least part of the phosphorylation
of EGFR in Fc:FasL-treated keratinocytes.
The phosphorylation of EGFR in response to Fc:FasL is
autocatalytic and determines the phosphorylation of
ERK and Akt To investigate whether the kinase activity of
EGFR itself is responsible for the phopshorylation of the
receptor in Fc:FasL-treated keratinocytes, we employed
LA1, an EGFR-neutralizing antibody (Kawamoto et al, 1992;
Ristow, 1996; Al Moustafa et al, 1999) and AG1478, a
small molecule inhibitor of the kinase activity of EGFR (Os-
herov and Levitzki, 1994). Indeed, both LA1 and AG1478
abrogated the ability of Fc:FasL to trigger EGFR phosphor-
ylation (Fig 8A, compare lanes 7–9 to lanes 10–12; Fig 8B,
compare lanes 7–9 to lanes 10–12). As expected, also
the Fc:FasL-triggered phosphorylation of ERK and Akt
was strongly inhibited by blocking EGFR (Fig 8A, compare
lanes 7–9 to lanes 10–12; Fig 8B, compare lanes 7–9 to
lanes 10–12).
Identiﬁcation of amphiregulin as an EGFR ligand
produced by apoptotic keratinocytes In an attempt to
identify the EGFR ligand(s) produced by apoptotic keratin-
Figure9
Role of amphiregulin (AR) in the Fc:FasL (Fas ligand)-induced
phosphorylation of epidermal growth factor receptor (EGFR). (A) A
neutralizing anti-AR antibody decreases both the basal and the
Fc:FasL-induced phosphorylation of EGFR. The cells were treated
with Fc:FasL. Where indicated, a neutralizing anti-AR antibody (50 mg
per mL) was given to the cells for 30 min before the treatment. Four
hours later, the phosphorylation state of EGFR was assessed in
immunoblot analyses using a phosphoepitope-specific antibody. (B)
ELISA detection of AR under untreated and Fc:FasL-treatment condi-
tions. Cells (as indicated, either HEKn-E6/E7 or HEKn, passage 6) were
washed of exogenous and endogenously produced growth factors and
the cells were placed in BKMexoGF. The medium was collected for
ELISA either immediately (a) or at the indicated times after the removal
of growth factors (b–e) in the absence (b, c) or in the presence (d, e) of
Fc:FasL. Error bars depict standard deviation from experimental points
in triplicates.
Figure 8
The activation of MEK, extracellular signal-activated kinase (ERK),
and protein kinase B (Akt)1 in response to Fc:FasL (Fas ligand) is
dependent on epidermal growth factor receptor (EGFR). (A) HEKn
(human epidermal kerationcytes, neonatal)-E6/E7 were treated with
Fc:FasL. Where indicated, the LA1 EGFR-blocking antibody (5 mg per
mL) was given to the cells for 30 min before the treatment. At the
indicated times, the phosphorylation states of EGFR, MEK, and ERK
were assessed in immunoblot analyses using phosphoepitope-specific
antibodies. The heavy chain of the LA1 antibody appears in the gel
because of internalization and/or adherence of the antibody to the cell
surface. (B) HEKn-E6/E7 were treated with Fc:FasL. Where indicated,
AG1478 (10 mM) or solvent vehicle (DMSO) were given to the cells for
30 min before the treatment. At the indicated times, the phosphorylat-
ion states of EGFR, ERK, and Akt1 were assessed in immunoblot
analyses using phosphoepitope-specific antibodies. Apoptosis was
assessed by determining the cleavage of poly(ADP)ribose polymerase.
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ocytes, we employed blocking antibodies against three
known EGFR ligands. Whereas antibodies neutralizing TGF-
a and HB-EGF had consistently little or no effect on the
Fc:FasL-induced EGFR phosphorylation (not shown), the
AR-neutralizing antibody was able to substantially reduce
both the basal and the Fc:FasL-induced phosphorylation of
EGFR (Fig 9A). These results are in agreement with recent
data indicating the importance of AR the autocrine activa-
tion of ERK in keratinocytes (Kansra et al, 2004). Further-
more, an ELISA detection of AR release by both HEKn and
HEKn–E6/E7 demonstrated the ability of these cells to pro-
duce AR constitutively (Fig 9B and C) and to further increase
the release of AR in response to Fc:FasL (Fig 9B, D and E).
We concluded, therefore, that AR is an important autocrine
regulator of EGFR activity in response to apoptotic stimuli.
The activation of EGFR, ERK, and Akt cannot prevent
the cell death caused by Fc:FasL We considered the
possibility that stimulating the potent pro-survival EGFR-Akt
and EGFR-ERK signaling pathways may decrease the cyto-
toxicity of FasL in keratinocytes. We tested this possibility
by interfering with the activation of either signaling pathway
singly or in combination. Thus, abrogating EGFR activation
by means of AG1478, blocked both the activation of ERK
and Akt (Fig 8B, compare lanes 7–9 to lanes 10–12). Ap-
plication of wortmannin, an inhibitor of phosphatidylinositol
3-kinase (Arcaro and Wymann, 1993), an upstream activator
of Akt (Franke et al, 1995), abrogated the activation of Akt
by Fc:FasL, but had a modest effect on the activation of
ERK (not shown). Conversely, U0126, an inhibitor of MEK
(Favata et al, 1998), abrogated the activation of ERK, but
had no effect on the activation of Akt by Fc:FasL (not
shown). Importantly, none of the employed inhibitors was
capable of affecting the pro-apoptotic action of Fc:FasL, as
determined by PARP cleavage (exemplified in Fig 8B for
AG1478). It appears, therefore, that, for keratinocytes di-
rectly targeted by FasL, the ligation of Fas triggers a dom-
inant cytotoxic response that cannot be counteracted by
the activation of EGFR, ERK, and Akt.
The findings described in this work can be summarized
in a model presented in Fig 10. We demonstrate the exist-
ence of a novel signaling pathway triggered by ligation of
Fas in keratinocytes. Downstream of the FasL/Fas-depend-
ent activation of caspases, one (AR) or more epidermis-
specific, membrane-bound forms of EGFR ligands are pro-
duced and processed by a proteolytic activity inhibitable by
ilomastat. The soluble EGFR ligands, in turn, activate EGFR
and trigger the activation of two downstream EGFR effector
pathways: the Ras-Raf-MEK-ERK pathway and the PI3K-
Akt pathway. Despite the potent pro-survival function of
EGFR in the epidermis (Sibilia et al, 2000 and references
therein), it appears that the ligation of Fas is dominant in
determining the fate of an individual keratinocyte, i.e., the
keratinocyte that has produced EGFR ligands in response
to Fas activation is unable to ‘‘benefit’’ from the anti-apo-
ptotic program it has initiated. What could be, then,
the function of the activation of EGFR, ERK, and Akt in
response to apoptotic stimuli in the epidermis? Work
performed by Trautmann et al (2000) on AD and nickel-
triggered ACD and by us on SADBE-triggered ACD (Fig 1)
indicates that apoptotic keratinocytes present in the ecze-
matous areas are surrounded by cells lacking any apoptotic
morphology (as in Fig 1, panel c). We speculate that the
EGFR ligands produced by apoptotic cells in the epidermis
act on non-apoptotic neighboring cells to trigger their pro-
liferation (in the case of basal keratinocytes) and/or migra-
tion into the areas of massive epidermal destruction, thus
preserving the barrier function of the skin.
Materials and Methods
Cells Primary explanted HEKn and all cell culture reagents were
from Cascade Biologics (Portland, Oregon). The derivation and
characterization of immortalized human epidermal keratinocytes
Figure 10
A model for the mechanism of Fc:FasL
(Fas ligand)-induced activation of epi-
dermal growth factor receptor, extra-
cellular signal-activated kinase, and
protein kinase B1 in keratinocytes.
See explanations in the text.
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(HEKn-E6/E7) has been described in Iordanov et al, 2002. Briefly,
primary human epidermal keratinocytes, neonatal (HEKn) were in-
fected with an amphitropic recombinant retroviral vector encoding
the E6 and E7 transforming proteins of human papilloma virus se-
rotype 16. HEKn and HEKn-E6/E7 were maintained in EpiLife basal
keratinocyte medium (BKM) (Cascade Biologics, Portland, Oregon)
supplemented with a semi-defined human keratinocyte growth
supplement (HKGS; the final concentrations of the components in
the supplemented medium are: bovine pituitary extract, 0.2% v/v;
bovine insulin, 5 mg per mL; hydrocortisone, 0.18 mg per mL;
bovine transferrin, 5 mg per mL; and human epidermal growth
factor, 0.2 ng per mL). BKM supplemented with HKGS is referred to
as BKMþ exoGF (BKM plus exogenous growth factors). Respec-
tively, BKM lacking HKGS is referred to as BKMexoGF (BKM
minus exogenous growth factors).
Chemicals and Fc:FasL All commonly used chemicals were from
Sigma Chemical Company (St. Louis, Missouri). Caspase inhibitors
(zVADfmk and zIETDfmk), AG1478, U0126, and wortmannin were
from Calbiochem (La Jolla, California). Ilomastat was from Biomol
(Plymouth Meeting, Pennsylvania). For all experiments, Fc:FasL
(Holler et al, 2003) was used at a final concentration of 250 ng per
mL except for the experiment shown in Fig 4A (500 ng per mL).
Preparation of cell lysates for immunoblot analysis To avoid
potential post-lysis modifications or degradation of proteins of in-
terest, the cells were harvested by direct lysis in 2  SDS-PAGE
sample-loading buffer, followed by heat denaturation at 951C for 5
min and ultrasonic shearing. Typically, the detached (dead) cells
were sedimented from the growth medium by centrifugation, lysed
in 2  SDS-PAGE sample-loading buffer, and combined with the
cell lysates from adherent cells. Cell lysates were stored at 701C.
Antibodies and immunoblot analyses The anti-Ki–67 antibody
was from Biomeda (Beaufort, South Carolina). The anti-K5 and -K1
antibodies were from BabCo. The Fas-blocking antibody ZB4 and
the EGFR-blocking antibody LA1 were from Upstate Cell Signaling
Solutions (Waltham, Massachusetts). The amphiregulin-, heparin-
binding EGF-, and TGF-a-blocking antibodies were from R&D
Systems. The antibodies against PARP (H–250), ERK1 (C-16),
EGFR (EGFR–1005), and the phosphorylated form of EGFR
(pY1173) were from Santa Cruz Biotechnologies (Santa Cruz,
California). The antibody against the phosphorylated form of EGFR
(pY1068) and the antibodies against the phosphorylated forms of
ERK, MEK, and PKB/Akt1 (S473), as well as the anti-caspase 8
antibody (clone 1C12), were from Cell Signaling Technology. The
separation of proteins in SDS-PAGE and the electrotransfer onto
polyvinylidene difluoride membranes (Millipore, Billerica, Massa-
chusetts) were performed by standard procedures. Immunoprob-
ing with specific antibodies and enhanced chemiluminescent
detection (DuPont NEN Research Products, Boston, Massachu-
setts) were performed following the instructions of the respective
manufacturers.
Immunohistochemistry, TUNEL, and ELISA The immunohisto-
chemical detection of Ki-67, TUNEL, and detection of AR release
by ELISA were performed following the protocols provided by the
respective manufacturers (Biomeda, Boehringer Mannheim/Roche,
and R&D Systems, Indianapolis, Indiana).
Experimental ACD SADBE was used to induce allergic contact
dermatitis in normal volunteers after informed consent documents
were obtained, under a protocol approved by the Institutional Re-
view Board of Oregon Health & Science University and conformed
to ethical guidelines of Declaration of Helsinki. Volunteers were
sensitized by applying 2% SADBE in acetone under occlusion to a
2 cm2 area of normal skin on the upper arm overnight. Volunteers
then washed the area thouroughly with soap and water. Volunteers
were then challenged with 0.5% SADBE to the volar forearm 2
weeks later. All volunteers displayed erythema and a typical ec-
zematous dermatitis 48 h after application. Four millimeter punch
biopsies from lesional and adjacent non-lesional skin were ob-
tained 2 and 7 d after the application of SADBE. Biopsy specimens
were cryopreserved in optimal cutting temperature (OCT) embed-
ding medium.
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